In the latest episode of The Genetics Podcast, Sano CEO Patrick Short sat down with Daniel O’Connor, an expert in regulatory policy for innovative medicines, particularly those focused on rare diseases. Daniel, who spent nearly 20 years at the MHRA (Medicines and Healthcare products Regulatory Agency) and recently joined the ABPI (Association of the British Pharmaceutical Industry), shared his extensive experience and insights into the regulatory landscape of rare disease drug development.
Background
The episode begins with Daniel discussing his background and career path. He spent 17 years at the MHRA, the UK's regulatory body for medicines, where he was deeply involved in regulatory policy and rare diseases. He then joined the ABPI, an association representing over 120 pharmaceutical companies, where he continues to advocate for making the UK a leading hub for research, development, and use of innovative medicines.
Defining modern rare diseases
Daniel highlighted the complexities of defining rare diseases in today's world. While it might seem straightforward, the advances in diagnostics and molecular sciences have added layers of complexity. Conditions once considered rare are now better understood due to molecular tools, revealing differences within rare diseases. This evolution in understanding requires a more nuanced approach to defining and categorizing rare diseases, which is crucial for developing effective policies and strategies.
Regulatory engagement in rare disease drug development
A significant part of the discussion focused on the importance of early engagement with regulatory bodies like the MHRA. Daniel emphasized that regulators are increasingly adopting open-door policies to facilitate discussions with developers of innovative products. The MHRA’s Innovation Office, for instance, offers a free-of-charge, informal consultation for novel medicines and technologies. This proactive engagement can help developers navigate the regulatory landscape more effectively.
Daniel discussed various regulatory incentives designed to support rare disease drug development, such as the orphan drug designation. These incentives, which include data protection periods and marketing exclusivity, are vital for encouraging investment in rare disease therapeutics. He also mentioned the UK’s Innovative Licensing and Access Pathway (ILAP) and the Early Access to Medicines Scheme (EAMS), which aim to streamline the development and approval processes, ensuring patients get timely access to new treatments.
Innovative approaches to clinical trial design
The conversation also touched on the unique challenges of designing clinical trials for rare diseases, such as small patient populations and ethical considerations. Daniel pointed out that regulators recognize these challenges and offer flexible licensing systems, like conditional marketing authorization and approval under exceptional circumstances. These systems allow for the approval of therapies based on limited data, with the expectation of further evidence generation post-approval.
Daniel shared his excitement about the potential of platform technologies like gene editing (CRISPR) and mRNA, which have shown great promise in recent years. He also emphasized the importance of drug repurposing and newborn screening as crucial areas for future development. These advances could significantly impact rare disease treatment by providing new therapeutic options and enabling early diagnosis and intervention.
Highlighting the need for international collaboration, Daniel discussed his involvement with the International Rare Disease Research Consortium (IRDiRC). Global cooperation is essential in rare disease research to pool resources and expertise, ensuring that patients worldwide benefit from advancements in diagnostics and therapeutics.
Summary
This episode provides an in-depth look at the complexities of rare disease drug development and the regulatory environment. Daniel O’Connor’s experience sheds light on the importance of early regulatory engagement, the value of international collaboration, and the potential of new technologies to advance treatment options for rare diseases. His insights are invaluable for anyone involved in the field, offering a practical perspective on the current landscape and future directions.
Listen here:
.png)
